trending Market Intelligence /marketintelligence/en/news-insights/trending/nfwmoew1n-fdsfytuu4z8g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

TRACON to fund cancer drug development with $38.7M private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


TRACON to fund cancer drug development with $38.7M private placement

San Diego-based TRACON Pharmaceuticals Inc. is looking to raise $38.7 million via the sale of 13.7 million shares priced $2.825 each.

Each share will come with a warrant to purchase an additional stock at $2.70 each.

The financing is led by Puissance Capital Management with participation from certain existing investors, including New Enterprise Associates and 683 Capital Partners LP.

After the placement is completed, the biotechnology company expects to appoint Ted Wang to its board.

Wang is the chief investment officer of Puissance Capital Management.

The company intends to use the proceeds to fund the development of its cancer drugs TRC105 and TRC253.